Skip to main content
. 2023 Dec 10;143(12):1139–1156. doi: 10.1182/blood.2023021199

Figure 1.

Figure 1.

Reclassification of established CMML and monocytosis cases based on the updated WHO22 and ICC22 classifications. (A) Schematic depiction of the main differences and changes between the WHO17, the ICC22, and the WHO22 classifications. (B) Diagnosis update of 1279 established CMML cases from the WHO17 to the ICC22 and the WHO22 classifications. “No CMML” stands for alternative diagnosis due to CMML criteria not being fulfilled. Notably, when evaluating all cases with absolute monocyte count (AMC) ≥1 × 109/L and ≥10% PB monocytes irrespective of their original diagnosis, only 69 cases (<0.01%) were not diagnosed as CMML at the time of workup. Of these 69 cases, 62 either had a concurrent diagnosis of lymphoma or non-CMML leukemia (n = 12) or received a CMML diagnosis during follow-up (n = 50). (C) Diagnosis update of 1054 monocytosis cases (AMC, 0.5 × 109/L-1 × 109/L and >10%; no prior CMML diagnosis) from the WHO17 to the ICC22, and the WHO22 classifications. AL, acute leukemia; CCUS, clonal cytopenia of unknown significance; CHIP, clonal hematopoiesis of indeterminate potential; LYM, lymphoma; MPN, myeloproliferative neoplasia; NM, nonmalignant.